You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Clinical characteristics of neonates between C.albicans and non-C.albicans

From: Epidemiology of Candida albicans and non-C.albicans of neonatal candidemia at a tertiary care hospital in western China

Variable C.albicans mean (95%CI) or n (%) non-C.albicans mean (95%CI) or n (%) P value odds ratio (OR) (95%CI)
Demographics
 gestational age (wks) 31.7 (27.6, 35.8) 31.5 (27.7, 36.3) 0.765  
 birth weight (g) 1670.0 (962.1,2377.9) 1417.6 (777.1,2058.1) 0.128  
 male gender, n (%) 22 (73.3) 22 (56.4) 0.150 0.47 (0.17–1.32)
 admission age 2.1 (2.0, 6.2) 1.1 (0.6, 1.6) 0.138  
Risk factors
 necrotizing enterocolitis 5 (16.7) 12 (30.8) 0.183 2.22 (0.69–7.21)
 neurodevelopmental impairment 7 (23.3) 8 (20.5) 0.778 0.85 (0.27–2.68)
 maternal underlying diseases 12 (40.0) 18 (46.2) 0.609 1.29 (0.50–3.36)
 assisted reproductive technology 5 (16.7) 19 (48.7) 0.008 4.75 (1.51–14.96)
 vaginal birth 19 (63.3) 23 (59.0) 0.713 1.20 (0.45–3.20)
 fetal membrane rupture (h) 16.4 (28.4, 61.2) 26.6 (36.0, 89.2) 0.459  
 congentital diseases 13 (43.3) 24 (61.5) 0.135 2.09 (0.80–5.51)
 abdominal surgery 4 (13.3) 6 (15.4) 0.811 1.18 (0.30–4.63)
 mechanical ventilation 14 (46.7) 29 (74.4) 0.021 3.31 (1.20–9.15)
 central venous catheter 14 (46.7) 27 (69.2) 0.061 2.57 (0.96–6.91)
 intubation 10 (33.3) 21 (53.8) 0.092 2.33 (0.87–6.26)
 pulmonary active substance use 7 (23.3) 9 (23.1) 0.980 0.99 (0.32–3.04)
 steroids use 6 (20.0) 9 (23.1) 0.759 1.20 (0.38–3.84)
 antacid use 3 (10.3) 8 (21.1) 0.250 2.31 (0.56–9.63)
 total parenteral nutrition 23 (76.7) 36 (92.3) 0.080 3.65 (0.86–15.57)
 hospitalization duration (d) 43.8 (19.1, 78.5) 49.1 (26.6, 71.6) 0.367  
 3rdcephalosporins use 16 (55.2) 23 (59.0) 0.754 1.17 (0.44–3.08)
 carbapenems use 21 (70.0) 30 (76.9) 0.517 1.43 (0.49–4.20)
 vancomycin use 4 (13.3) 6 (15.4) 0.811 1.18 (0.30–4.63)
 multiple antibiotic use 19 (63.3) 18 (46.2) 0.158 0.50 (0.19–1.31)
 antibiotic therapeutic duration (d) 28.1 (10.0, 46.2) 38.0 (19.3, 56.7) 0.033  
 prophylaxis antifungal therapy 19 (63.3) 32 (82.1) 0.084 2.65 (0.88–7.99)
 antifungal therapeutic duration (d) 7.9 (2.3, 13.5) 8.8 (2.3, 15.3) 0.535  
Outcome
 death 1 (3.3) 5 (12.8) 0.197 4.27 (0.47–38.62)